New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
14:08 EDTARIAARIAD slumps after FDA requires warning on newly approved drug
ARIAD Pharmaceuticals (ARIA) is retreating after the company said that the FDA had approved the company's leukemia treatment, but will require it to include a warning on the drug's box. The warning will state that the drug, Iclusig, can cause blood clots and liver toxicity, ARIAD disclosed earlier today. In a note to investors, Citigroup wrote that the Street had not expected the company to be forced to issue such a warning. The firm, however, views the FDA's decision to grant accelerated approval to the drug as positive and it maintains a Buy rating on the stock. In mid-afternoon trading, ARIAD fell $2.33, or 9.76%, to $21.55.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
12:11 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
09:00 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTARIAARIAD announces PRAC of EMA recommends Iclusig for continued EU use
Subscribe for More Information
October 6, 2014
07:36 EDTARIAARIAD, Bellicum announce revised license agreement for cell-signaling technology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use